All In Biotech

Drug Trial Radar · NCT07190248

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 675 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

675

Planned (sponsor's estimate)

Start

Oct 8, 2025

Primary completion

Dec 7, 2029

Study completion Aug 6, 2032

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Sep 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The goal of this study is to learn if people who receive calderasib with SC pembrolizumab live longer without the cancer growing or spreading than in people who receive SC pembrolizumab with chemotherapy.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • CalderasibDrug

    Administered as an oral tablet

  • Pembrolizumab (+) Berahyaluronidase alfaBiological

    Administered as a SC injection

  • PemetrexedDrug

    Administered as an IV Infusion

  • CisplatinDrug

    Administered as an IV Infusion

  • CarboplatinDrug

    Administered as an IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) in Participants with Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥1%Time frame: Up to approximately 48 months

Locations

226 sites in 30 countries. Site status is shown where the registry gives one.

  • Central Alabama Research ( Site 0108)

    Birmingham, Alabama · Recruiting

  • Beverly Hills Cancer Center ( Site 0142)

    Beverly Hills, California · Recruiting

  • University of Connecticut Health Center ( Site 0130)

    Farmington, Connecticut · Recruiting

  • Stamford Hospital ( Site 0126)

    Stamford, Connecticut · Recruiting

  • The Oncology Institute of Hope and Innovation ( Site 0161)

    Fort Lauderdale, Florida · Recruiting

  • Mount Sinai Cancer Center ( Site 0137)

    Miami Beach, Florida · Completed

  • Low Country Cancer Care ( Site 0156)

    Savannah, Georgia · Recruiting

  • Indiana University Health Arnett Cancer Center ( Site 0116)

    Lafayette, Indiana · Recruiting

  • New England Cancer Specialists ( Site 0139)

    Westbrook, Maine · Recruiting

  • Minneapolis VA Medical Center ( Site 0145)

    Minneapolis, Minnesota · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0152)

    Hackensack, New Jersey · Recruiting

  • New York Oncology Hematology, P.C. ( Site 0119)

    Albany, New York · Recruiting

  • Wilmot Cancer Institute ( Site 0141)

    Rochester, New York · Recruiting

  • St. Charles Health System, Inc ( Site 0146)

    Bend, Oregon · Recruiting

  • Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0111)

    Lancaster, Pennsylvania · Recruiting

  • Hematology Oncology Associates of Fredericksburg ( Site 9550)

    Fredericksburg, Virginia · Recruiting

  • Bon Secours Cancer Institute at St. Francis ( Site 0148)

    Midlothian, Virginia · Recruiting

  • Blue Ridge Cancer Care ( Site 0144)

    Roanoke, Virginia · Recruiting

  • WVU Cancer Institute ( Site 0153)

    Morgantown, West Virginia · Recruiting

  • Hospital Italiano de Cordoba ( Site 0308)

    Córdoba, Argentina · Recruiting

  • CEMAIC ( Site 0309)

    Córdoba, Argentina · Recruiting

  • Instituto Alexander Fleming ( Site 0311)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Instituto de Investigaciones Clinicas Mar del Plata ( Site 0300)

    Mar del Plata, Buenos Aires, Argentina · Recruiting

  • Genesis Care- Campbelltown ( Site 2907)

    Campbelltown, New South Wales, Australia · Recruiting

  • Northern Beaches Hospital ( Site 2905)

    Frenchs Forest, New South Wales, Australia · Recruiting

  • The Prince Charles Hospital ( Site 2903)

    Brisbane, Queensland, Australia · Recruiting

  • Mater Hospital Brisbane ( Site 2906)

    South Brisbane, Queensland, Australia · Recruiting

  • Peninsula & South Eastern Haematology and Oncology Group ( Site 2908)

    Frankston, Victoria, Australia · Recruiting

  • Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 1001)

    Vienna, Austria · Recruiting

  • Klinikum Klagenfurt am Wörthersee ( Site 1002)

    Klagenfurt, Carinthia, Austria · Recruiting

  • Medizinische Universität Graz-Klinische Abteilung für Pulmonologie ( Site 1005)

    Graz, Styria, Austria · Recruiting

  • Clinical Chc Montlégia ( Site 3901)

    Liège, Belgium · Recruiting

  • Algemeen Ziekenhuis Klina ( Site 3904)

    Brasschaat, Antwerpen, Belgium · Recruiting

  • CHU Helora - Hôpital de La Louvière - Site Jolimont ( Site 3900)

    La Louvière, Hainaut, Belgium · Recruiting

  • Ziekenhuis Oost-Limburg, Campus St.-Jan ( Site 3903)

    Genk, Limburg, Belgium · Recruiting

  • VITAZ ( Site 3902)

    Sint-Niklaas, Oost-Vlaanderen, Belgium · Recruiting

  • IBCC - Núcleo de Pesquisa e Ensino ( Site 0417)

    São Paulo, Brazil · Recruiting

  • CRIO - CENTRO REGIONAL INTEGRADO DE ONCOLOGIA ( Site 0412)

    Fortaleza, Ceará, Brazil · Recruiting

  • Hospital Santa Rita de Cassia ( Site 0403)

    Vitória, Espírito Santo, Brazil · Recruiting

  • Real Hospital Portugues ( Site 0418)

    Recife, Pernambuco, Brazil · Recruiting

Showing 40 of 226 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.